List of therapeutic monoclonal antibodies

This is a list of therapeutic, diagnostic and preventive monoclonal antibodies, antibodies that are clones of a single parent cell. When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies.

Types of monoclonal antibodies with other structures than naturally occurring antibodies.

The abbreviations in the column Type are as follows:

This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.

NameTrade nameTypeSourceTarget ApprovedUse
3F8mabmouseGD2 ganglioside neuroblastoma
8H9[1]mabmouseB7-H3 neuroblastoma, sarcoma, metastatic brain cancers
Abagovomab[2]mabmouseCA-125 (imitation) ovarian cancer
Abciximab[3]ReoProFabchimericCD41 (integrin alpha-IIb) Yplatelet aggregation inhibitor
Abituzumab[4]mabhumanizedCD51 cancer
Abrezekimab[5]Fabhumanizedinterleukin 13 ?
Abrilumab[6]mabhumanintegrin α4β7 inflammatory bowel disease, ulcerative colitis, Crohn's disease
Actoxumab[6]mabhumanClostridium difficile Clostridium difficile colitis
Adalimumab[7]HumiramabhumanTNF-α Yrheumatoid arthritis, Crohn's disease, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, hemolytic disease of the newborn
Adecatumumab[8]mabhumanEpCAM prostate and breast cancer
Aducanumab[9]mabhumanbeta-amyloid Alzheimer's disease
Afasevikumab[10]mabhumanIL17A and IL17F multiple sclerosis
Afelimomab[3]F(ab')2mouseTNF-α sepsis
Alacizumab pegol[11]F(ab')2humanizedVEGFR2 cancer
Alemtuzumab[12]Lemtrada, CampathmabhumanizedCD52 Ymultiple sclerosis
Alirocumab[13]PraluentmabhumanPCSK9 Yhypercholesterolemia
Altumomab pentetateHybri-ceakermabmouseCarcinoembryonic antigen (CEA) colorectal cancer (diagnosis)
Amatuximab[14]mabchimericmesothelin cancer
AmivantamabbsmabhumanEpidermal growth factor receptor (EGFR), cMet Ynon-small cell lung cancer
Anatumomab mafenatox[15]FabmouseTumor-associated glycoprotein 72 (TAG-72) non-small cell lung cancer
Andecaliximab[16]mabchimericgelatinase B gastric cancer or gastroesophageal junction adenocarcinoma
Anetumab ravtansine[4]mabhumanmesothelin (MSLN) cancer
Anifrolumab[4]mabhumaninterferon α/β receptor systemic lupus erythematosus
AnsuvimabEbangamabhumanEbola virus glycoprotein Ytreatment of Zaire ebolavirus (Ebola virus)
Anrukinzumab[11] (= IMA-638)[17]mabhumanizedIL-13 asthma
Apolizumab[18]mabhumanizedHLA-DR ? hematological cancers
Aprutumab ixadotin[19]mabhumanFGFR2 ?
Arcitumomab[20]CEA-ScanFab'mouseCarcinoembryonic antigen (CEA) gastrointestinal cancers (diagnosis)
Ascrinvacumab[10]mabhumanactivin receptor-like kinase 1 cancer
Aselizumab[21]mabhumanizedL-selectin (CD62L) severely injured patients
Atezolizumab[22]TecentriqmabhumanizedPD-L1 Ycancer
Atidortoxumab[23]mabhumanStaphylococcus aureus alpha toxin ?
Atinumab[14]mabhumanRTN4 ?
Atoltivimabmabhuman part of Atoltivimab/maftivimab/odesivimab for treatment of Zaire ebolavirus (Ebola virus)
Atoltivimab/maftivimab/odesivimabInmazebmabhuman Ytreatment of Zaire ebolavirus (Ebola virus)
Atorolimumab[3]mabhumanRhesus factor hemolytic disease of the newborn
Avelumab[10]BavenciomabhumanPD-L1 Ycancer
Azintuxizumab vedotin[24]mabchimeric/humanizedCD319 cancer
Bamlanivimabmabhuman COVID-19
Bapineuzumab[25]mabhumanizedbeta amyloid Alzheimer's disease
Basiliximab[26]SimulectmabchimericCD25 (α chain of IL-2 receptor) Yprevention of organ transplant rejections
Bavituximab[2]mabchimericphosphatidylserine cancer, viral infections
BCD-100?humanPD-1 melanoma
Bectumomab[26]LymphoScanFab'mouseCD22 non-Hodgkin's lymphoma (detection)
Begelomab[6]mabmouseDPP4 ?
Belantamab mafodotin[5]BlenrepmabhumanizedB-cell maturation antigen (BCMA) Yrelapsed or refractory multiple myeloma
Belimumab[27]BenlystamabhumanB-cell activating factor (BAFF) Ysystemic lupus erythematosus without renal or CNS involvement
Bemarituzumab[23]mabhumanizedFGFR2 gastric cancer or gastroesophageal junction adenocarcinoma
Benralizumab[28]FasenramabhumanizedCD125 Yasthma
Berlimatoxumab[23]mabhumanStaphylococcus aureus bi-component leukocidin ?
Bermekimab[26]XilonixmabhumanIL1A colorectal cancer
Bersanlimab[5]mabhumanICAM-1 ?
Bertilimumab[21]mabhumanCCL11 (eotaxin-1) severe allergic disorders
Besilesomab[29]ScintimunmabmouseCarcinoembryonic antigen (CEA)-related antigen inflammatory lesions and metastases (detection)
Bevacizumab[12]AvastinmabhumanizedVEGF-A Ymetastatic cancer, retinopathy of prematurity
Bezlotoxumab[26]ZinplavamabhumanClostridium difficile YClostridium difficile colitis
Biciromab[26]FibriScintFab'mousefibrin II, beta chain thromboembolism (diagnosis)
Bimagrumab[30]mabhumanACVR2B myostatin inhibitor
Bimekizumab[9]mabhumanizedIL 17A and IL 17F ankylosing spondylitis, psoriasis
Birtamimabmabchimericserum amyloid A protein amyloidosis
Bivatuzumab[26]mabhumanizedCD44 v6 squamous cell carcinoma
Bleselumab[10]mabhumanCD40 organ transplant rejection
Blinatumomab[26]BlincytoBiTEmouseCD19 Ypre-B Acute lymphoblastic leukemia (ALL) (CD19+)
Blontuvetmab[31]BlontressmabveterinaryCD20
Blosozumab[32]mabhumanizedSOST osteoporosis
Bococizumab[26]mabhumanizedPCSK9 dyslipidemia
Brazikumab[16]mabhumanIL23 Crohn's disease
Brentuximab vedotin[26]AdcentrismabchimericCD30 (TNFRSF8) YHodgkin's lymphoma

anaplastic large-cell lymphoma

Briakinumab[26]mabhumanIL-12, IL-23 psoriasis, rheumatoid arthritis, inflammatory bowel diseases, multiple sclerosis
Brodalumab[32]SiliqmabhumanIL-17 YPlaque psoriasis
Brolucizumab[22]BeovuscFvhumanizedvascular endothelial growth factor A (VEGFA) Ywet age-related macular degeneration
Brontictuzumab[6]mabhumanizedNotch 1 cancer
Burosumab[16]CrysvitamabhumanFGF 23 YX-linked hypophosphatemia
Cabiralizumab[31]mabhumanizedCSF1R metastatic pancreatic cancer
Camidanlumab tesirine[23]mabhumanCD25 (α chain of IL-2 receptor) B-cell Hodgkin's lymphoma, non-Hodgkin lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia
Camrelizumab[19]mabhumanizedPD-1 hepatocellular carcinoma
Canakinumab[33]IlarismabhumanIL-1 Ycryopyrin-associated periodic syndrome
Cantuzumab mertansine[32]mabhumanizedCanAg (a glycoform of MUC1) colorectal cancer etc.
Cantuzumab ravtansine[32]mabhumanizedCanAg (a glycoform of MUC1) cancers
Caplacizumab[34]CablivisdAbhumanizedVWF Ythrombotic thrombocytopenic purpura, thrombosis
Casirivimabmabhumanspike protein receptor binding domain (RBD) of SARS-CoV-2COVID-19
Capromab[26]ProstascintmabmouseGlutamate carboxypeptidase II Yprostate cancer (detection)
Carlumab[14]mabhumanMCP-1 oncology/immune indications
Carotuximab[31]mabchimericendoglin angiosarcoma
Catumaxomab[25]Removab3functrat/mouse hybridEpCAM, CD3 Yovarian cancer, malignant ascites, gastric cancer
cBR96-doxorubicin immunoconjugatemabhumanizedLewis-Y antigen cancer
Cedelizumab[35]mabhumanizedCD4 prevention of organ transplant rejections, treatment of autoimmune diseases
Cemiplimab[26]LibtayomabhumanPDCD1 Ycutaneous squamous cell carcinoma
Cergutuzumab amunaleukin[10]mabhumanizedIL2 cancer
Certolizumab pegol[33]CimziaFab'humanizedTNF-α YCrohn's disease, rheumatoid arthritis, axial spondyloarthritis, psoriasis arthritis
Cetrelimab[5]mabhumanPD-1 cancer
Cetuximab[26]ErbituxmabchimericEpidermal growth factor receptor (EGFR) Ymetastatic colorectal cancer and head and neck cancer
Cibisatamab[5]mabhumanizedCEACAM5 cancer
Cirmtuzumab[26]?humanizedROR1 chronic lymphocytic leukemia
Citatuzumab bogatox[36]FabhumanizedEpCAM ovarian cancer and other solid tumors
Cixutumumab[26]mabhumanIGF-1 receptor (CD221) solid tumors
Clazakizumab[37]mabhumanizedInterleukin 6 (IL-6) rheumatoid arthritis
Clenoliximab[26]mabchimericCD4 rheumatoid arthritis
Clivatuzumab tetraxetan[26]hPAM4-CidemabhumanizedMUC1 pancreatic cancer
Codrituzumab[4]mabhumanizedglypican 3 cancer
Cofetuzumab pelidotin[23]mabhumanizedPTK7 cancer
Coltuximab ravtansine[4]mabchimericCD19 cancer
Conatumumab[36]mabhumanTRAIL-R2 cancer
Concizumab[30]mabhumanizedtissue factor pathway inhibitor (TFPI) bleeding
Cosfroviximab[24]ZMappmabchimericebolavirus glycoprotein Ebola virus
Crenezumab[26]mabhumanized1-40-β-amyloid Alzheimer's disease
Crizanlizumab[19]Adakveomabhumanizedselectin P Ysickle-cell disease
Crotedumab[31]mabhumanglucagon receptor (GCGR) diabetes
CR6261mabhumanInfluenza A hemagglutinin infectious disease/influenza A
Cusatuzumab[5]mabhumanizedCD70 cancer
Dacetuzumab[11]mabhumanizedCD40 hematologic cancers
Daclizumab[38]ZenapaxmabhumanizedCD25 (α chain of IL-2 receptor) Yprevention of organ transplant rejections, multiple sclerosis
DalotuzumabmabhumanizedIGF-1 receptor (CD221) cancer etc.
Dapirolizumab pegol[9]mabhumanizedCD154 (CD40L) ?
Daratumumab[39]DarzalexmabhumanCD38 Ymultiple myeloma
Dectrekumab[22]mabhumanIL-13 ?
DemcizumabmabhumanizedDLL4 cancer
Denintuzumab mafodotin[6]mabhumanizedCD19 cancer
Denosumab[40]ProliamabhumanRANKL Yosteoporosis, bone metastases etc.
Depatuxizumab mafodotin[19]mabchimeric/humanizedEGFR glioblastoma
Derlotuximab biotinmabchimerichistone complex recurrent glioblastoma multiforme
DetumomabmabmouseB-lymphoma cell lymphoma
Dezamizumab[19]mabhumanizedserum amyloid P component ?
DinutuximabUnituxinmabchimericGD2 ganglioside Yneuroblastoma
Dinutuximab betaQarzibamabchimericGD2 ganglioside Yneuroblastoma
Diridavumabmabhumanhemagglutinin influenza A
Domagrozumab[31]mabhumanizedGDF-8 Duchenne muscular dystrophy
Dorlimomab aritox[41]F(ab')2mouse? ?
Dostarlimab[42]mabhumanizedPCDP1 cancer
DrozitumabmabhumanDR5 cancer etc.
DS-8201?humanizedHER2 gastric or gastroesophageal junction adenocarcinoma
Duligotuzumab[13]mabhumanizedERBB3 (HER3) testicular cancer
Dupilumab[30]DupixentmabhumanIL-4Rα Yatopic dermatitis, asthma, nasal polyps
Durvalumab[22]ImfinzimabhumanPD-L1 Ycancer
DusigitumabmabhumanILGF2 B-cell malignancies
Duvortuxizumab[24]scFvchimeric/humanizedCD19, CD3E cancer
Ecromeximab[18]mabchimericGD3 ganglioside malignant melanoma
Eculizumab[18]SolirismabhumanizedC5 Yparoxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome
Edobacomabmabmouseendotoxin sepsis caused by Gram-negative bacteria
EdrecolomabPanorexmabmouseEpCAM colorectal carcinoma
Efalizumab[7]RaptivamabhumanizedLFA-1 (CD11a) psoriasis (blocks T-cell migration)
Efungumab[2]MycograbscFvhumanHsp90 invasive Candida infection
Eldelumab[4]mabhumaninterferon gamma-induced protein Crohn's disease, ulcerative colitis
Elezanumab[19]mabhumanrepulsive guidance molecule A (RGMA) spinal cord injury and multiple sclerosis
Elgemtumab[22]mabhumanERBB3 (HER3) cancer
ElotuzumabEmplicitimabhumanizedSLAMF7 Ymultiple myeloma
ElsilimomabmabmouseIL-6 ?
Emactuzumab[6]mabhumanizedCSF1R cancer
Emapalumab[19]Gamifantmabhumaninterferon gamma Yhemophagocytic lymphohistiocytosis
EmibetuzumabmabhumanizedhHGFR cancer
Emicizumab[10]Hemlibramabhumanizedactivated F9, F10 Yhaemophilia A
Enapotamab vedotin[5]mabhumanAXL cancer
EnavatuzumabmabhumanizedTWEAK receptor cancer etc.
Enfortumab vedotinPadcevmabhumannectin-4 Yurothelial cancer
Enlimomab pegol[43]mabmouseICAM-1 (CD54) ?
Enoblituzumab[19]mabhumanizedCD276 cancer
EnokizumabmabhumanizedIL9 asthma
Enoticumab[13]mabhumanDLL4 ?
EnsituximabmabchimericMUC5AC cancer
EpcoritamabbsmabhumanCD3, CD20 B-cell lymphoma
Epitumomab cituxetan[44]mabmouseepisialin ?
EpratuzumabmabhumanizedCD22 cancer, systemic lupus erythematosus (SLE)
Eptinezumab[19]Vyeptimabhumanizedcalcitonin gene-related peptide Ymigraine
Erenumab[19]Aimovigmabhumancalcitonin gene-related peptide receptor (CGRP) Ymigraine
Erlizumab[45]F(ab')2humanizedITGB2 (CD18) heart attack, stroke, traumatic shock
Ertumaxomab[25]Rexomun3functrat/mouse hybridHER2/neu, CD3 Ybreast cancer etc.
EtaracizumabAbegrinmabhumanizedintegrin αvβ3 Ymelanoma, prostate cancer, ovarian cancer etc.
Etigilimab[5]mabhumanizedTIGIT ?
Etrolizumab[14]mabhumanizedintegrin β7 inflammatory bowel disease
Evinacumabmabhumanangiopoietin 3 dyslipidemia
Evolocumab[30]RepathamabhumanPCSK9 Yhypercholesterolemia
Exbivirumab[46]mabhumanhepatitis B surface antigen hepatitis B
Fanolesomab[15]NeutroSpecmabmouseCD15 appendicitis (diagnosis)
Faralimomabmabmouseinterferon receptor ?
Faricimab[5]mabhumanizedVEGF-A and Ang-2 angiogenesis, ocular vascular diseases
Farletuzumabmabhumanizedfolate receptor 1 ovarian cancer
FasinumabmabhumanNerve growth factor (HNGF) acute sciatic pain
FBTA05[47][48]Lymphomun3functrat/mouse hybridCD20 chronic lymphocytic leukaemia
Felvizumabmabhumanizedrespiratory syncytial virus respiratory syncytial virus infection
Fezakinumab[49][50]mabhumanIL-22 rheumatoid arthritis, psoriasis
Fibatuzumab[10]mabhumanizedephrin receptor A3 ?
FiclatuzumabmabhumanizedHepatocyte growth factor (HGF) cancer etc.
FigitumumabmabhumanIGF-1 receptor (CD221) adrenocortical carcinoma, non-small cell lung carcinoma etc.
Firivumab[6]mabhumaninfluenza A virus hemagglutinin ?
FlanvotumabmabhumanTYRP1 (glycoprotein 75) melanoma
FletikumabmabhumanIL 20 rheumatoid arthritis
Flotetuzumab[5]di-scFvhumanizedIL 3 receptor hematological malignancies
Fontolizumab[18]HuZAFmabhumanizedIFN-γ Crohn's disease etc.
Foralumab[51]mabhumanCD3 epsilon ?
Foravirumab[36]mabhumanrabies virus glycoprotein rabies (prophylaxis)
Fremanezumab[19]Ajovymabhumanizedcalcitonin gene-related peptide alpha Ymigraine and cluster headache
Fresolimumab[39]mabhumanTGF-β idiopathic pulmonary fibrosis, focal segmental glomerulosclerosis, cancer
Frovocimab[42]mabhumanizedPCSK9 hypercholesterolemia
Frunevetmab[24]mabveterinarynerve growth factor (NGF) ?
FulranumabmabhumanNerve growth factor (NGF) pain
Futuximab[13]mabchimericEpidermal growth factor receptor (EGFR) cancer
Galcanezumab[31]Emgalitymabhumanizedcalcitonin Ymigraine
GaliximabmabchimericCD80 B-cell lymphoma
GancotamabscFvhumanHER2/neu cancer
GanitumabmabhumanIGF-1 receptor (CD221) cancer
Gantenerumab[33]mabhumanbeta amyloid Alzheimer's disease
Gatipotuzumab[24]mabhumanizedMUC1 cancer
Gavilimomab[45]mabmouseCD147 (basigin) graft versus host disease
Gedivumab[24]mabhumanhemagglutinin HA ?
Gemtuzumab ozogamicin[19]MylotargmabhumanizedCD33 Yacute myelogenous leukemia
GevokizumabmabhumanizedIL-1β diabetes etc.
Gilvetmab[24]mabveterinaryPCDC1 ?
Gimsilumab[23]mabhumanCSF2 rheumatoid arthritis
Girentuximab[39]Rencarexmabchimericcarbonic anhydrase 9 (CA-IX) clear cell renal cell carcinoma[52]
Glembatumumab vedotin[28][53]mabhumanGPNMB melanoma, breast cancer
Golimumab[46]SimponimabhumanTNF-α Yrheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis
GomiliximabmabchimericCD23 (IgE receptor) allergic asthma
Gosuranemabmabhumanizedtau protein progressive supranuclear palsy
GuselkumabTremfyamabhumanIL23 Ypsoriasis
Ianalumab[23]mabhumanBAFF-R autoimmune hepatitis
Ibalizumab[33]TrogarzomabhumanizedCD4 YHIV infection
IBI308?humanPD-1 squamous cell non-small cell lung cancer
Ibritumomab tiuxetanZevalinmabmouseCD20 Ynon-Hodgkin's lymphoma
IcrucumabmabhumanVEGFR-1 cancer etc.
Idarucizumab[4]Praxbindmabhumanizeddabigatran Yreversal of anticoagulant effects of dabigatran
Ifabotuzumab[19]mabhumanizedEPHA3 glioblastoma multiforme[54]
IgovomabIndimacis-125F(ab')2mouseCA-125 ovarian cancer (diagnosis)
Iladatuzumab vedotin[23]mabhumanizedCD79B cancer
IMAB362mabhumanCLDN18.2 gastrointestinal adenocarcinomas and pancreatic tumor
Imalumab[6]mabhumanmacrophage migration inhibitory factor (MIF) cancer
Imaprelimab[5]mabhumanizedmelanoma cell adhesion molecule (MCAM) ?
ImciromabMyoscintmabmousecardiac myosin Ycardiac imaging
Imdevimabmabhumanspike protein receptor binding domain (RBD) of SARS-CoV-2COVID-19
Imgatuzumab[13]mabhumanizedEpidermal growth factor receptor (EGFR) cancer
Inclacumab[34]mabhumanselectin P cardiovascular disease
Indatuximab ravtansine[32]mabchimericSDC1 cancer
Indusatumab vedotin[22]mabhumanGUCY2C cancer
Inebilizumab[10]UpliznamabhumanizedCD19 Ycancer, systemic sclerosis, multiple sclerosis
InfliximabRemicademabchimericTNF-α Yrheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease, ulcerative colitis
Intetumumab[55][56]mabhumanCD51 solid tumors (prostate cancer, melanoma)
InolimomabmabmouseCD25 (α chain of IL-2 receptor) graft versus host disease
Inotuzumab ozogamicin[29]BesponsamabhumanizedCD22 YAcute lymphoblastic leukemia (ALL)
Ipilimumab[40]YervoymabhumanCD152 Ymelanoma
Iomab-B?mouseCD45 ablation of bone marrow
Iratumumab[40]mabhumanCD30 (TNFRSF8) Hodgkin's lymphoma
IsatuximabSarclisamabchimericCD38 Ymultiple myeloma
Iscalimab[5]mabhumanCD40 ?
Istiratumab[23]mabhumanIGF1R, CD221 advanced solid tumors
Itolizumab[51]AlzumabmabhumanizedCD6 Ypsoriasis
IxekizumabTaltzmabhumanizedIL 17A Yautoimmune diseases
KeliximabmabchimericCD4 chronic asthma
Labetuzumab[7]CEA-CidemabhumanizedCarcinoembryonic antigen (CEA) colorectal cancer
Lacnotuzumab[24]mabhumanizedCSF1, macrophage colony stimulating factor (MCSF) cancer
Ladiratuzumab vedotin[23]mabhumanizedLIV-1 cancer
Lampalizumab[13]FabhumanizedComplement factor D (CFD) geographic atrophy secondary to age-related macular degeneration
Lanadelumab[31]Takhzyromabhumankallikrein Yangioedema
Landogrozumab[10]mabhumanizedGDF-8 muscle wasting disorders
Laprituximab emtansine[31]mabchimericepidermal growth factor receptor (EGFR) ?
Larcaviximab[24]mabchimericebolavirus glycoprotein Ebola virus
LebrikizumabmabhumanizedIL-13 asthma
Lemalesomab[45]mabmouseNCA-90 (granulocyte antigen) diagnostic agent
Lendalizumab[31]mabhumanizedC5 ?
Lenvervimab[5]mabhumanizedhepatitis B surfage antigen hepatitis B
Lenzilumab[6]mabhumanCSF2 chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia
Lerdelimumab[15]mabhumanTGF beta 2 reduction of scarring after glaucoma surgery
Leronlimab[5]mabhumanizedCCR5 breast cancer, HIV
Lesofavumab[24]mabhumanhemagglutinin HA ?
Letolizumab[24]scFvhumanizedtumor necrosis factor related activation protein (TRAP) inflammatory diseases
Lexatumumab[2]mabhumanTRAIL-R2 cancer
Libivirumab[46]mabhumanhepatitis B surface antigen hepatitis B
Lifastuzumab vedotinmabhumanizedphosphate-sodium co-transporter cancer
Ligelizumab[13]mabhumanizedIGHE severe asthma and chronic spontaneous urticaria
Loncastuximab tesirine[23]mabchimericCD19 cancer
Losatuxizumab vedotin[24]mabchimeric/humanizedepidermal growth receptor factor (EGRF), ERBB1 HER1 cancer
Lilotomab satetraxetan[22]mabmouseCD37 cancer
LintuzumabmabhumanizedCD33 cancer
Lirilumab[13]mabhumanKIR2D solid and hematological cancers
Lodelcizumab[30]mabhumanizedPCSK9 hypercholesterolemia
Lokivetmab[22]Cytopoint[57]mabveterinaryCanis lupus familiaris IL31 Yclinical signs of atopic dermatitis in dogs[57]
Lorvotuzumab mertansinemabhumanizedCD56 cancer
Lucatumumab[11]mabhumanCD40 multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's lymphoma
Lulizumab pegol[6]mabhumanizedCD28 autoimmune diseases
Lumiliximab[8]mabchimericCD23 (IgE receptor) chronic lymphocytic leukemia
Lumretuzumab[6]mabhumanizedERBB3 (HER3) cancer
Lupartumab[19]mabhuman?
Lupartumab amadotin[19]mabhumanLYPD3 ?
Lutikizumab[19]mabhumanizedinterleukin 1 alpha ?
Maftivimabmabhuman part of Atoltivimab/maftivimab/odesivimab for treatment of Zaire ebolavirus (Ebola virus)
Mapatumumab[25]mabhumanTRAIL-R1 cancer
MargetuximabMargenza[58]mabhumanizedHER2 Ybreast cancer
Marstacimabmabhumantissue factor pathway inhibitor (TFPI) bleeding with hemophilia
Maslimomab?mouseT-cell receptor
Mavrilimumab[28]mabhumanGMCSF receptor α-chain rheumatoid arthritis
Matuzumab[21]mabhumanizedEpidermal growth factor receptor (EGFR) colorectal, lung and stomach cancer
Mepolizumab[35]BosatriamabhumanizedIL-5 Yasthma and white blood cell diseases
Metelimumab[21]mabhumanTGF beta 1 systemic scleroderma
Milatuzumab[11]mabhumanizedCD74 multiple myeloma and other hematological malignancies
MinretumomabmabmouseTAG-72 tumor detection (and therapy?)
Mirikizumab[23]mabhumanizedIL23A psoriasis
Mirvetuximab soravtansinemabchimericfolate receptor alpha ovarian cancer
MitumomabmabmouseGD3 ganglioside small cell lung carcinoma
ModotuximabmabchimericEGFR extracellular domain III cancer
Mogamulizumab[14]PoteligeomabhumanizedCCR4 Yadult T-cell leukemia/lymphoma
Monalizumab[10]mabhumanizedNKG2A rheumatoid arthritis, gynecologic malignancies, and other cancers
Morolimumab[59]mabhumanRhesus factor
Mosunetuzumab[23]mabhumanizedCD3E, MS4A1, CD20 cancer
Motavizumab[2]Numaxmabhumanizedrespiratory syncytial virus respiratory syncytial virus (prevention)
Moxetumomab pasudotoxLumoxitimabmouseCD22 Yhairy cell leukemia
Muromonab-CD3Orthoclone OKT3mabmouseCD3 prevention of organ transplant rejections
Nacolomab tafenatoxFabmouseC242 antigen colorectal cancer
Namilumab[14]mabhumanCSF2
Naptumomab estafenatox[60]Fabmouse5T4 non-small cell lung carcinoma, renal cell carcinoma
Naratuximab emtansine[31]mabchimericCD37
NarnatumabmabhumanMST1R (aka RON) cancer
Natalizumab[59]Tysabrimabhumanizedintegrin α4 Ymultiple sclerosis, Crohn's disease
Navicixizumab[31]mabchimeric/humanizedDLL4 and VEGFA cancer
Navivumab[10]mabhumaninfluenza A virus hemagglutinin HA
NaxitamabDanyelza?humanizedc-Met Yhigh-risk neuroblastoma and refractory osteomedullary disease
Nebacumabmabhumanendotoxin sepsis
Necitumumab[61]PortrazzamabhumanEpidermal growth factor receptor (EGFR) Ynon-small cell lung carcinoma
Nemolizumab[22]mabhumanizedIL31RA eczema[62]
NEOD001?humanizedamyloid primary systemic amyloidosis
NerelimomabmabmouseTNF-α ?
Nesvacumabmabhumanangiopoietin 2 cancer
Netakimab[5]Efleiramabchimericinterleukin 17A plaque psoriasis
Nimotuzumab[40][63]BioMab-EGFR, Theracim, Theralocmabhumanizedepidermal growth factor receptor (EGFR) Ysquamous cell carcinoma, head and neck cancer, nasopharyngeal cancer, glioma
NirsevimabmabhumanRSV fusion glycoprotein respiratory syncytial virus
Nivolumab[6]OpdivomabhumanPD-1 Ycancer
Nofetumomab merpentanVerlumaFabmouse? cancer (diagnosis)
ObiltoxaximabAnthimmabchimericBacillus anthracis anthrax YBacillus anthracis spores
ObinutuzumabGazyvamabhumanizedCD20 Ychronic lymphatic leukemia
OcaratuzumabmabhumanizedCD20 cancer
Ocrelizumab[2]OcrevusmabhumanizedCD20 Ymultiple sclerosis
Odesivimabmabhuman part of Atoltivimab/maftivimab/odesivimab for treatment of Zaire ebolavirus (Ebola virus)
OdulimomabmabmouseLFA-1 (CD11a) prevention of organ transplant rejections, immunological diseases
Ofatumumab[25]Arzerra, Kesimpta[64]mabhumanCD20 Ychronic lymphocytic leukemia

multiple sclerosis[64]

OlaratumabLartruvomabhumanPDGF-R α Ycancer
Oleclumab[24]mabhuman5'-nucleotidase pancreatic and colorectal cancer
Olendalizumab[24]mabhumanizedcomplement C5a systemic lupus erythematosus, lupus nephritis, acute graft-versus-hose disease
Olokizumab[51]mabhumanizedIL6 rheumatoid arthritis
Omalizumab[45]XolairmabhumanizedIgE Fc region Yallergic asthma
Omburtamab[42]mabmouseCD276 cancer
OMS721?humanMASP-2 atypical hemolytic uremic syndrome
OnartuzumabFabhumanizedhuman scatter factor receptor kinase cancer
Ontuxizumabmabchimeric/humanizedTEM1 cancer
Onvatilimab[5]mabhumanVISTA (protein) (VSIR) ?
OpicinumabmabhumanLINGO-1 multiple sclerosis
Oportuzumab monatox[61]ViciniumscFvhumanizedEpCAM bladder cancer
Oregovomab[15]OvaRexmabmouseCA-125 ovarian cancer
Orticumab[13]mabhumanoxLDL
Otelixizumab[11]mabchimeric/humanizedCD3 diabetes mellitus type 1
OtilimabmabhumanGMCSF osteoarthritis, rheumatoid arthritis
OtlertuzumabmabhumanizedCD37 cancer
Oxelumab[32]mabhumanOX-40 asthma
OzanezumabmabhumanizedNOGO-A ALS and multiple sclerosis
Ozoralizumab[32]mabhumanizedTNF-α inflammation
Pagibaximab[25]mabchimericlipoteichoic acid sepsis (Staphylococcus)
PalivizumabSynagis, AbbosynagismabhumanizedF protein of respiratory syncytial virus Yrespiratory syncytial virus (prevention)
Pamrevlumab[10]mabhumanconnective tissue growth factor (CTGF) idiopathic pulmonary fibrosis (IPF), pancreatic cancer
Panitumumab[46]Vectibixmabhumanepidermal growth factor receptor (EGFR) Ycolorectal cancer
Pankomabmabhumanizedtumor specific glycosylation of MUC1 ovarian cancer
Panobacumab[61]mabhumanPseudomonas aeruginosa Pseudomonas aeruginosa infection
Parsatuzumab[13]mabhumanizedEGFL7 cancer
Pascolizumab[18]mabhumanizedIL-4 asthma
Pasotuxizumab[6]mabchimeric/humanizedfolate hydrolase cancer
Pateclizumab[32]mabhumanizedlymphotoxin alpha (LTA) TNF
Patritumab[34]mabhumanERBB3 (HER3) cancer
PDR001?humanizedPD-1 melanoma
Pembrolizumab[9]KeytrudamabhumanizedPD-1 Ymelanoma and other cancers
PemtumomabTheragyn?mouseMUC1 cancer
Perakizumab[13]mabhumanizedIL 17A arthritis
PertuzumabPerjetamabhumanizedHER2/neu Ycancer
Pexelizumab[15]scFvhumanizedC5 reduction of side effects of cardiac surgery
Pidilizumab[30]mabhumanizedPD-1 cancer and infectious diseases
Pinatuzumab vedotin[30]mabhumanizedCD22 cancer
Pintumomabmabmouseadenocarcinoma antigen adenocarcinoma (imaging)
Placulumab[13]mabhumanhuman TNF pain and inflammatory diseases
Prezalumab[31]mabhumanhuman TNF
Plozalizumab[10]mabhumanizedCCR2 diabetic nephropathy and arteriovenous graft patency
Pogalizumab[31]mabhumanizedtumor necrosis factor receptor (TNFR) superfamily member 4 ?
Polatuzumab vedotin[30]PolivymabhumanizedCD79B Ydiffuse large B-cell lymphoma
Ponezumabmabhumanizedhuman beta-amyloid Alzheimer's disease
Porgaviximab[24]mabchimericZaire ebolavirus glycoprotein Ebola virus disease
Prasinezumab[23]mabhumanizedsodium cyclopentadienide (NACP) Parkinson's disease
Prezalizumab[31]mabhumanizedinducible T-cell co-stimulatory ligand (ICOSL) ?
PriliximabmabchimericCD4 Crohn's disease, multiple sclerosis
Pritoxaximab[30]mabchimericE. coli shiga toxin type-1 ?
Pritumumabmabhumanvimentin brain cancer
PRO 140?humanizedCCR5 HIV infection
Quilizumab[34]mabhumanizedIGHE asthma
Racotumomab[61]VaxiramabmouseNGNA ganglioside Ynon-small cell lung cancer
Radretumab[14]mabhumanfibronectin extra domain-B cancer
Rafivirumab[36]mabhumanrabies virus glycoprotein rabies (prophylaxis)
RalpancizumabmabhumanizedPCSK9 dyslipidemia
RamucirumabCyramzamabhumanVEGFR2 Ysolid tumors
RanevetmabmabveterinaryNGF osteoarthritis in dogs
Ranibizumab[8]LucentisFabhumanizedVEGF-A Ymacular degeneration (wet form)
Raxibacumab[29]mabhumananthrax toxin, protective antigen Yanthrax (prophylaxis and treatment)
Ravagalimab[5]mabhumanizedCD40 Crohn's disease
Ravulizumab[23]UltomirismabhumanizedC5 Yparoxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome
Refanezumabmabhumanizedmyelin-associated glycoprotein recovery of motor function after stroke
Regavirumabmabhumancytomegalovirus glycoprotein B cytomegalovirus infection
REGN-EB3mabhuman 3 mabs for ebola infection with FDA orphan drug status
RelatlimabmabhumanLAG3 melanoma
Remtolumab[19]mabhumaninterleukin 17 alpha, TNF ?
Reslizumab[7]CinqairmabhumanizedIL-5 Yinflammations of the airways, skin and gastrointestinal tract
Rilotumumabmabhumanhepatocyte growth factor (HGF) solid tumors
Rinucumabmabhumanplatelet-derived growth factor receptor beta neovascular age-related macular degeneration
Risankizumab[10]SkyrizimabhumanizedIL23A YCrohn's disease, psoriasis, psoriatic arthritis, and asthma
RituximabMabThera, RituxanmabchimericCD20 Ylymphomas, leukemias, some autoimmune disorders
Rivabazumab pegol[10]mabhumanizedPseudomonas aeruginosa type III secretion system ?
RobatumumabmabhumanIGF-1 receptor (CD221) cancer
RmabRabiShield?humanrabies virus G glycoprotein Ypost-exposure prophylaxis of rabies
Roledumab[51]mabhumanRHD (gene) (RHD) Rh disease
Romilkimab[5]mabchimeric/humanizedinterleukin 13 ?
RomosozumabEvenitymabhumanizedsclerostin Yosteoporosis
Rontalizumab[39]mabhumanizedIFN-α systemic lupus erythematosus
Rosmantuzumab[19]mabhumanizedroot plate-specific spondin 3 cancer
Rovalpituzumab tesirine[10]mabhumanizedDLL3 small cell lung cancer
Rovelizumab[35]LeukArrestmabhumanizedCD11, CD18 Yhaemorrhagic shock etc.
Rozanolixizumab[19]mabchimeric/humanizedFCGRT Immune thrombocytopenic purpura (ITP), myasthenia gravis
Ruplizumab[12]AntovamabhumanizedCD154 (CD40L) Yrheumatic diseases
SA237?humanizedIL-6R neuromyelitis optica and neuromyelitis optica spectrum disorders
Sacituzumab govitecan[19]TrodelvymabhumanizedTROP-2 Ytriple-negative breast cancer
Samalizumab[32]mabhumanizedCD200 cancer
Samrotamab vedotin[5]mabchimeric/humanizedLRRC15 cancer
Sarilumab[34]KevzaramabhumanIL6 Yrheumatoid arthritis, ankylosing spondylitis
Satralizumab[65]EnspryngmabhumanizedIL6 receptor Yneuromyelitis optica
Satumomab pendetidemabmouseTAG-72 cancer (diagnosis)
SecukinumabCosentyxmabhumanIL 17A Yuveitis, rheumatoid arthritis psoriasis
Selicrelumab[24]mabhumanCD40 ?
Seribantumab[30]mabhumanERBB3 (HER3) cancer
Setoxaximab[30]mabchimericE. coli shiga toxin type-2 ?
Setrusumab[23]mabhumansclerostin (SOST) ?
Sevirumab?humancytomegalovirus cytomegalovirus infection
SibrotuzumabmabhumanizedFAP (gene) (FAP) cancer
SGN-CD19AmabhumanizedCD19 acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma
SHP647?humanmucosal addressin cell adhesion molecule Crohn's disease
Sifalimumab[14]mabhumanIFN-α systemic lupus erythematosus (SLE), dermatomyositis, polymyositis
SiltuximabSylvantmabchimericIL-6 Ycancer
Simtuzumab[13]mabhumanizedLOXL2 fibrosis
Siplizumab[18]mabhumanizedCD2 psoriasis, graft-versus-host disease (prevention)
Sirtratumab vedotin[23]mabhumanSLITRK6 cancer
SirukumabmabhumanIL-6 rheumatoid arthritis
Sofituzumab vedotinmabhumanizedCA-125 ovarian cancer
Solanezumab[61]mabhumanizedbeta amyloid Alzheimer's disease
Solitomab[34]BiTEmouseEpCAM gastrointestinal, lung, and other cancers
Sonepcizumab[66]?humanizedsphingosine-1-phosphate choroidal and retinal neovascularization
Sontuzumab[63]mabhumanizedepisialin
Spartalizumab[23]mabhumanizedPDCD1, CD279 melanoma
Stamulumab[2]mabhumanmyostatin muscular dystrophy
SulesomabLeukoScanFab'mouseNCA-90 (granulocyte antigen) osteomyelitis (imaging)
Suptavumab[19]mabhumanRSVFR medically attended lower respiratory disease
Sutimlimab[5]mabchimeric/humanizedC1s cold agglutinin disease
Suvizumab[28]mabhumanizedHIV-1 viral infections
Suvratoxumab[24]mabhumanStaphylococcus aureus alpha toxin nosocomial pneumonia
Tabalumab[32]mabhumanB-cell activating factor (BAFF) B-cell cancers
Tacatuzumab tetraxetanAFP-Cidemabhumanizedalpha-fetoprotein cancer
Tadocizumab[63]Fabhumanizedintegrin αIIbβ3 percutaneous coronary intervention
Tafasitamab[35]Monjuvimabhumanized (from mouse)CD19 Yrelapsed or refractory diffuse large B-cell lymphoma
Talacotuzumab[23]mabhumanizedCD123 leukemia etc.
Talizumab[27]mabhumanizedIgE allergic reaction
TalquetamabbsmabhumanGPRC5D, CD3 Yrelapsed or refractory multiple myeloma
Tamtuvetmab[31]TactressmabveterinaryCD52
Tanezumab[36]mabhumanizednerve growth factor (NGF) pain
Taplitumomab paptox[45]mabmouseCD19 cancer
TarextumabmabhumanNotch receptor cancer
Tavolimabmabchimeric/humanizedCD134 cancer
TeclistamabbsmabhumanB-cell maturation antigen (BCMA), CD3 Yrelapsed or refractory multiple myeloma
Tefibazumab[29]Aurexismabhumanizedclumping factor A Staphylococcus aureus infection
Telimomab aritoxFabmouse?
Telisotuzumab[19]mabhumanizedHGFR cancer
Telisotuzumab vedotin[19]mabhumanizedHGFR cancer
Tenatumomab[11]mabmousetenascin C cancer
Teneliximab[18]mabchimericCD40 autoimmune diseases and prevention of organ transplant rejection
Teplizumab[33]mabhumanizedCD3 diabetes mellitus type 1
Tepoditamab[5]mabhumandendritic cell-associated lectin 2 cancer
TeprotumumabTepezzamabhumanIGF-1 receptor (CD221) Ythyroid eye disease
Tesidolumab[22]mabhumanC5
TetulomabmabhumanizedCD37 cancer[67]
Tezepelumab[10]mabhumanthymic stromal lymphopoietin (TSLP) asthma, atopic dermatitis
TGN1412?humanizedCD28 chronic lymphocytic leukemia, rheumatoid arthritis
Tibulizumab[23]mabhumanizedB-cell activating factor (BAFF) autoimmune disorders
TildrakizumabIlumyamabhumanizedIL23 Yimmunologically mediated inflammatory disorders
Tigatuzumab[11]mabhumanizedTRAIL-R2 cancer
Timigutuzumab[24]mabhumanizedHER2 cancer
Timolumab[31]mabhumanAOC3
tiragolumab[23]mabhuman
Tiragotumab[23]mabhumanTIGIT cancer
Tislelizumab[23]mabhumanizedPCDC1, CD279 non-small cell lung cancer
Tisotumab vedotin[10]mabhumancoagulation factor III relapsed or refractory cervical cancer[68]
TNX-650?humanizedIL-13 Hodgkin's lymphoma
Tocilizumab[8]Actemra, RoActemramabhumanizedIL-6 receptor Yrheumatoid arthritis
Tomuzotuximab[24]mabhumanizedepidermal growth factor receptor (EGFR), HER1 cancer
Toralizumab[18]mabhumanizedCD154 (CD40L) rheumatoid arthritis, lupus nephritis etc.
Tosatoxumab[4]mabhumanStaphylococcus aureus
TositumomabBexxar?mouseCD20 Yfollicular lymphoma
TovetumabmabhumanPDGFRA cancer
TralokinumabmabhumanIL-13 asthma, atopic dermatitis
TrastuzumabHerceptinmabhumanizedHER2/neu Ybreast cancer
Trastuzumab duocarmazine[19]KadcylamabhumanizedHER2/neu Ybreast cancer
Trastuzumab emtansineKadcylamabhumanizedHER2/neu Ybreast cancer
TRBS07[69]Ektomab3funct?GD2 ganglioside melanoma
Tregalizumab[14]mabhumanizedCD4
Tremelimumab[33]mabhumanCTLA-4 non-small cell lung, head & neck, urothelial cancer
Trevogrumabmabhumangrowth differentiation factor 8 muscle atrophy due to orthopedic disuse and sarcopenia
Tucotuzumab celmoleukin[40][63]mabhumanizedEpCAM cancer
Tuvirumab?humanhepatitis B virus chronic hepatitis B
Ublituximab[14]mabchimericMS4A1 multiple sclerosis, chronic lymphocytic leukemia
Ulocuplumab[9]mabhumanCXCR4 (CD184) hematologic malignancies
Urelumab[14]mabhuman4-1BB (CD137) cancer etc.
Urtoxazumab[8]mabhumanizedEscherichia coli diarrhoea caused by E. coli
Ustekinumab[36]StelaramabhumanIL-12, IL-23 Ymultiple sclerosis, psoriasis, psoriatic arthritis
Utomilumab[19]mabhuman4-1BB (CD137) diffuse large B-cell lymphoma
Vadastuximab talirine[10]mabchimericCD33 Acute myeloid leukemia
Vanalimab[5]mabhumanizedCD40 ?
Vandortuzumab vedotin[22]mabhumanizedSTEAP1 cancer
VantictumabmabhumanFrizzled receptor cancer
Vanucizumab[6]mabhumanizedangiopoietin 2 cancer
Vapaliximab[18]mabchimericAOC3 (VAP-1)
Varisacumab[24]mabhumanVEGF-A angiogenesis
Varlilumab[6]mabhumanCD27 solid tumors and hematologic malignancies
Vatelizumab[32]mabhumanizedITGA2 (CD49b)
Vedolizumab[61]Entyviomabhumanizedintegrin α4β7 YCrohn's disease, ulcerative colitis
Veltuzumab[11]mabhumanizedCD20 non-Hodgkin's lymphoma
VepalimomabmabmouseAOC3 (VAP-1) inflammation
Vesencumab[14]mabhumanNRP1 solid malignancies
Visilizumab[45]NuvionmabhumanizedCD3 Crohn's disease, ulcerative colitis
Vobarilizumab[31]scFvhumanizedIL6R inflammatory autoimmune diseases
Volociximab[25]mabchimericintegrin α5β1 solid tumors
Vonlerolizumab[24]mabhumanizedCD134 cancer
Vopratelimab[5]mabhumanizedCD278, aka ICOS ?
Vorsetuzumab mafodotinmabhumanizedCD70 cancer
VotumumabHumaSPECTmabhumantumor antigen CTAA16.88 colorectal tumors
Vunakizumab[19]mabhumanizedinterleukin 17 alpha ?
Xentuzumab[31]mabhumanizedIGF1, IGF2 ?
XMAB-5574?humanizedCD19 diffuse large B-cell lymphoma
Zalutumumab[25]mabhumanEpidermal growth factor receptor (EGFR) squamous cell carcinoma of the head and neck
Zanolimumab[29]mabhumanCD4 rheumatoid arthritis, psoriasis, T-cell lymphoma
Zatuximab[13]mabchimericHER1 cancer
Zenocutuzumab[23]mabhumanizedERBB3, HER3 cancer
Ziralimumab[45]mabhumanCD147 (basigin) ?
Zolbetuximab[23] (=IMAB362, Claudiximab)mabchimericClaudin 18 Isoform 2 gastric cancer, gastrointestinal adenocarcinoma and pancreatic cancer
Zolimomab aritoxmabmouseCD5 systemic lupus erythematosus, graft-versus-host disease

References

  1. "United Therapeutics 10-K report". Retrieved 5 November 2011.
  2. World Health Organization (2006). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 95" (PDF). WHO Drug Information. 20 (2).
  3. World Health Organization (1998). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 80" (PDF). WHO Drug Information. 12 (4).
  4. World Health Organization (2013). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 109" (PDF). WHO Drug Information. 27 (2).
  5. World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 118" (PDF). WHO Drug Information. 31 (4).
  6. World Health Organization (2014). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 111" (PDF). WHO Drug Information. 28 (2).
  7. World Health Organization (2001). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 85" (PDF). WHO Drug Information. 15 (2).
  8. World Health Organization (2004). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 90" (PDF). WHO Drug Information. 18 (1).
  9. World Health Organization (2013). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 110" (PDF). WHO Drug Information. 27 (4).
  10. World Health Organization (2015). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 113" (PDF). WHO Drug Information. 29 (2).
  11. World Health Organization (2007). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 98" (PDF). WHO Drug Information. 21 (4).
  12. World Health Organization (2000). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 83" (PDF). WHO Drug Information. 14 (2).
  13. World Health Organization (2012). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 107" (PDF). WHO Drug Information. 26 (2).
  14. World Health Organization (2010). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 104" (PDF). WHO Drug Information. 24 (4).
  15. World Health Organization (2002). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 86" (PDF). WHO Drug Information. 16 (1).
  16. World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 115" (PDF). WHO Drug Information. 30 (2).
  17. "Wyeth.com | Complete Project Listing". Wyeth. 2008. Archived from the original on June 12, 2008. Retrieved November 19, 2008.
  18. World Health Organization (2002). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 87" (PDF). WHO Drug Information. 16 (2).
  19. World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 77" (PDF). WHO Drug Information. 31 (1).
  20. World Health Organization (1995). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 74" (PDF). WHO Drug Information. 9 (4).
  21. World Health Organization (2003). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 88" (PDF). WHO Drug Information. 17 (1).
  22. World Health Organization (2014). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 112" (PDF). WHO Drug Information. 28 (4).
  23. World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 117" (PDF). WHO Drug Information. 31 (2).
  24. World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 116" (PDF). WHO Drug Information. 30 (4).
  25. World Health Organization (2008). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 93" (PDF). WHO Drug Information. 19 (2).
  26. World Health Organization (2019). International Nonproprietary Names (INN) for biological and biotechnological substances (PDF). World Health Organization (WHO). WHO/EMP/RHT/TSN/2019.1. Retrieved 22 January 2020.
  27. World Health Organization (2003). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 89" (PDF). WHO Drug Information. 17 (3).
  28. World Health Organization (2009). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 102" (PDF). WHO Drug Information. 23 (4).
  29. World Health Organization (2004). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 92" (PDF). WHO Drug Information. 18 (4).
  30. World Health Organization (2012). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 108" (PDF). WHO Drug Information. 26 (4).
  31. World Health Organization (2015). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 114" (PDF). WHO Drug Information. 29 (4).
  32. World Health Organization (2011). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 105" (PDF). WHO Drug Information. 25 (2).
  33. World Health Organization (2007). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 97" (PDF). WHO Drug Information. 21 (2).
  34. World Health Organization (2011). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 106" (PDF). WHO Drug Information. 25 (4).
  35. World Health Organization (1999). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 81" (PDF). WHO Drug Information. 13 (2).
  36. World Health Organization (2008). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 99" (PDF). WHO Drug Information. 22 (2).
  37. "BMS Shells Out $85M Up Front for Alder's Mid-Stage Rheumatoid Arthritis Antibody". Genetic Engineering & Biotechnology News. 10 November 2009.
  38. World Health Organization (1997). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 78" (PDF). WHO Drug Information. 11 (4).
  39. World Health Organization (2009). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 101" (PDF). WHO Drug Information. 23 (2).
  40. World Health Organization (2005). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 94" (PDF). WHO Drug Information. 19 (4).
  41. World Health Organization (1991). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 66" (PDF). WHO Drug Information. 5 (4).
  42. World Health Organization (2018). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 119" (PDF). WHO Drug Information. 32 (2).
  43. World Health Organization (1997). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 77" (PDF). WHO Drug Information. 11 (2).
  44. World Health Organization (2004). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 51" (PDF). WHO Drug Information. 18 (1).
  45. World Health Organization (2000). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 84" (PDF). WHO Drug Information. 14 (4).
  46. World Health Organization (2004). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 91" (PDF). WHO Drug Information. 18 (2).
  47. Buhmann, R; Simoes, B; Stanglmaier, M; Yang, T; Faltin, M; Bund, D; Lindhofer, H; Kolb, HJ; et al. (2008). "Immunotherapy of recurrent B–cell malignancies after allo SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion". Bone Marrow Transplantation. 43 (5): 383–397. doi:10.1038/bmt.2008.323. PMID 18850012.
  48. Boehrer, S; Schroeder, Petra; Mueller, Tina; Atz, Judith; Chow, Kai Uwe; et al. (2011). "Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanisms". Anti-Cancer Drugs. 12 (10): 3085–3091. doi:10.1097/CAD.0b013e328344887f. PMID 21637160. S2CID 29327089.
  49. Clinical trial number NCT00883896 for "Study to Evaluate the Safety and Efficacy of ILV-094 in Subjects With Rheumatoid Arthritis" at ClinicalTrials.gov
  50. Clinical trial number NCT00563524 for "Study Evaluating the Safety and Tolerability of ILV-094 in Subjects With Psoriasis" at ClinicalTrials.gov
  51. World Health Organization (2011). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 103" (PDF). WHO Drug Information.
  52. "Prometheus Obtains Exclusive US Commercialization Rights for RENCAREX®".
  53. NCI Drug Dictionary: Glemtumumab vedotin
  54. "Results from Cure Brain Cancer Foundation-funded trial show promise". www.curebraincancer.org.au. Retrieved 2019-06-14.
  55. Clinical trial number NCT00537381 for "A Study of the Safety and Effectiveness of CNTO 95 in Patients With Metastatic Hormone Refractory Prostate Cancer" at ClinicalTrials.gov
  56. Clinical trial number NCT00246012 for "A Study of the Safety and Efficacy CNTO 95 in Subjects With Advanced Melanoma" at ClinicalTrials.gov
  57. Guthrie, Arlo (27 June 2017). "Zoetis launches breakthrough treatment for canine atopic dermatitis". VetNurse News. Retrieved 2018-07-06.
  58. "Margenza: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 17 December 2020.
  59. World Health Organization (1998). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 79" (PDF). WHO Drug Information. 12 (2).
  60. World Health Organization (2006). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 96" (PDF). WHO Drug Information. 20 (4).
  61. World Health Organization (2008). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 100 (prepublication copy)" (PDF). WHO Drug Information.
  62. Ruzicka, Thomas; Hanifin, Jon M.; Furue, Masutaka; Pulka, Grazyna; Mlynarczyk, Izabela; Wollenberg, Andreas; Galus, Ryszard; Etoh, Takafumi; Mihara, Ryosuke; Yoshida, Hiroki; Stewart, Jonathan; Kabashima, Kenji; XCIMA Study Group (2017). "Anti–Interleukin-31 Receptor a Antibody for Atopic Dermatitis". New England Journal of Medicine. 376 (9): 826–835. doi:10.1056/NEJMoa1606490. PMID 28249150. S2CID 205100502.
  63. World Health Organization (2006). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 56" (PDF). WHO Drug Information. 20 (3).
  64. "FDA approves Novartis Kesimpta (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis" (Press release). Novartis. 20 August 2020. Retrieved 21 August 2020.
  65. World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 78". WHO Drug Information. 31 (3). hdl:10665/330961.
  66. Xie, B.; Shen, J.; Dong, A.; Rashid, A.; Stoller, G.; Campochiaro, P. A. (2009). "Blockade of Sphingosine-1-phosphate Reduces Macrophage Influx and Retinal and Choroidal Neovascularization". Journal of Cellular Physiology. 218 (1): 192–198. doi:10.1002/jcp.21588. PMC 2905312. PMID 18781584.
  67. Jostein Dahle; Ada H. V. Repetto-Llamazares; Camilla S. Mollatt; Katrine B. Melhus; Oyvind S. Bruland; Arne Kolstad; Roy H. Larsen (January 2013). "Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma". Anticancer Research. 33 (1): 85–95. PMID 23267131.
  68. Wright, Rob (13 February 2018). "Seattle Genetics Legacy Of Partnering". Life Science Leader. Beyond The Printed Page. Retrieved 22 February 2018.
  69. Ruf, P; Jäger, M; Ellwart, J; Wosch, S; Kusterer, E; Lindhofer, H; et al. (2004). "Two new trifunctional antibodies for the therapy of human malignant melanoma". International Journal of Cancer. 108 (5): 725–732. doi:10.1002/ijc.11630. PMID 14696099. S2CID 25197165.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.